Five pharma CDMO stocks with robust revenue growth in Q2FY27

Discover five CDMO stocks demonstrating strong growth momentum in Q2FY27, backed by rising revenues and expanding opportunities.
Read the full story on Mint Opens livemint.com in a new tab
This is a short summary of a story published by Mint, shown with a link to the original. The full story, photo and reporting belong to Mint.











